Wientjes, Maike H. M. http://orcid.org/0000-0002-6666-9378
Atiqi, Sadaf
Wolbink, Gerrit Jan
Nurmohamed, Michael T.
Boers, Maarten
Rispens, Theo
de Vries, Annick
van Vollenhoven, Ronald F.
van den Bemt, Bart J. F.
den Broeder, Alfons A.
Funding for this research was provided by:
ZonMw (8481 01 006)
Article History
Received: 2 April 2021
Accepted: 4 June 2021
First Online: 19 June 2021
Declarations
:
: The study received primary ethical review board approval (number NL69841.091.19) on 24 September 2019. Ethics approval was obtained for all participating centres from the central Commissie Mensgebonden Onderzoek (CMO, committee of human research) Regio Arnhem Nijmegen, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, the Netherlands. Written, informed consent to participate will be obtained from all participants prior to inclusion. The trial is registered at Dutch Trial Register, NL8210, date 3 December 2019.
: Not applicable.
: Michael T. Nurmohamed: consulting fees from AbbVie, Celgene, Celltrion, Eli Lilly, Janssen and Sanofi; speaker’s fees from AbbVie, Bristol-Myers Squibb, Eli Lilly, Roche and Sanofi; and research funding from AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, MSD, Mundipharma, Novartis, Pfizer, Roche and Sanofi. Ronald F van Vollenhoven: research support (institutional grants)—BMS, GSK, Lilly and UCB; support for educational programmes (institutional grants)—Pfizer and Roche; consultancy, for which institutional and/or personal honoraria were received—AbbVie, AstraZeneca, Biogen, Biotest, Celgene, Galapagos, Gilead, Janssen, Pfizer, Servier and UCB; speaker, for which institutional and/or personal honoraria were received—AbbVie, Galapagos, Janssen, Pfizer and UCB. The other authors declare that they have no competing interests.